Balaxi Pharmaceuticals Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 547.21 million compared to INR 863.85 million a year ago. Revenue was INR 550.01 million compared to INR 905.23 million a year ago. Net income was INR 144.29 million compared to INR 154.87 million a year ago. Basic earnings per share from continuing operations was INR 2.82 compared to INR 3.098 a year ago. Diluted earnings per share from continuing operations was INR 2.812 compared to INR 3.098 a year ago.
For the six months, sales was INR 1,206.76 million compared to INR 1,691.7 million a year ago. Revenue was INR 1,199.48 million compared to INR 1,765.92 million a year ago. Net loss was INR 269.14 million compared to net income of INR 296.33 million a year ago. Basic loss per share from continuing operations was INR 5.266 compared to basic earnings per share from continuing operations of INR 5.926 a year ago.